Decitabine. MGI Pharma Inc/SuperGen Inc.
Decitabine is a DNA methyltransferase inhibitor under development by SuperGen Inc and MGI Pharma Inc for the potential treatment of a range of hematological malignancies, including myelodysplastic syndrome, solid tumors and sickle cell disease.
Arthur
Chris
C
Royal North Shore Hospital, Hematology Department, St Leonards, Sydney, NSW 2065, Australia. carthur@med.usyd.edu.au
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors; D000077209:Decitabine; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology
D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine